The PPARα agonist palmitoylethanolamide (PEA) has well-known anti-inflammatory effects, and a very recent study identified the putative mechanisms by which this compound could represent a promising adjuvant in the current COVID-19 therapeutic protocols [67]. This evidence concerns the gene PPARA and COVID-19.